期刊
IMMUNOLOGIC RESEARCH
卷 48, 期 1-3, 页码 122-146出版社
HUMANA PRESS INC
DOI: 10.1007/s12026-010-8172-z
关键词
Gamma-herpesviruses; Vaccine; EBV; KSHV; MHV-68
类别
资金
- NIH [DE18337, AI42927, CA148250, T32 AI49823, F32AI084327, DE19085, DE15752]
- Stop Cancer Foundation
Due to the oncogenic potential associated with persistent infection of human gamma-herpesviruses, including Epstein-Barr virus (EBV or HHV-4) and Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8), vaccine development has focused on subunit vaccines. However, the results using an animal model of mouse infection with a related rodent virus, murine gamma-herpesvirus 68 (MHV-68, gamma HV-68, or MuHV-4), have shown that the only effective vaccination strategy is based on live attenuated viruses, including viruses engineered to be incapable of establishing persistence. Vaccination with a virus lacking persistence would eliminate many potential complications. Progress in understanding persistent infections of EBV and KSHV raises the possibility of engineering a live attenuated virus without persistence. Therefore, we should keep the option open for developing a live EBV or KSHV vaccine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据